TNXP Tonix Pharmaceuticals Holding Corp

Price (delayed)

$0.5634

Market cap

$1.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$132.48

Enterprise value

$4.45M

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's ...

Highlights
TNXP's EPS has soared by 75% YoY and by 40% from the previous quarter
The company's revenue rose by 32% QoQ
The company's equity fell by 35% YoY but it rose by 2.5% QoQ
TNXP's quick ratio has plunged by 94% YoY and by 74% from the previous quarter
TNXP's gross margin is down by 3.6% from the previous quarter

Key stats

What are the main financial stats of TNXP
Market
Shares outstanding
2.99M
Market cap
$1.68M
Enterprise value
$4.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0
Price to sales (P/S)
0.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.43
Earnings
Revenue
$10.25M
EBIT
-$98.59M
EBITDA
-$93.98M
Free cash flow
-$89.87M
Per share
EPS
-$132.48
Free cash flow per share
-$35.56
Book value per share
$145.1
Revenue per share
$4.06
TBVPS
$49.41
Balance sheet
Total assets
$135.34M
Total liabilities
$27.2M
Debt
$9.82M
Equity
$108.14M
Working capital
$9.62M
Liquidity
Debt to equity
0.09
Current ratio
1.47
Quick ratio
0.34
Net debt/EBITDA
-0.03
Margins
EBITDA margin
-916.9%
Gross margin
37.6%
Net margin
-961.9%
Operating margin
-1,032.5%
Efficiency
Return on assets
-67%
Return on equity
-83%
Return on invested capital
-92.3%
Return on capital employed
-85.8%
Return on sales
-961.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TNXP stock price

How has the Tonix Pharmaceuticals Holding stock price performed over time
Intraday
0.61%
1 week
-6.1%
1 month
-56.66%
1 year
-66.06%
YTD
40.85%
QTD
-19.51%

Financial performance

How have Tonix Pharmaceuticals Holding's revenue and profit performed over time
Revenue
$10.25M
Gross profit
$3.85M
Operating income
-$105.83M
Net income
-$98.59M
Gross margin
37.6%
Net margin
-961.9%
The net margin rose by 36% since the previous quarter
The company's revenue rose by 32% QoQ
Tonix Pharmaceuticals Holding's operating margin has increased by 32% from the previous quarter
The gross profit has grown by 27% from the previous quarter

Growth

What is Tonix Pharmaceuticals Holding's growth rate over time

Valuation

What is Tonix Pharmaceuticals Holding stock price valuation
P/E
N/A
P/B
0
P/S
0.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.43
TNXP's EPS has soared by 75% YoY and by 40% from the previous quarter
The P/B is 100% lower than the 5-year quarterly average of 0.7 and 100% lower than the last 4 quarters average of 0.1
The company's equity fell by 35% YoY but it rose by 2.5% QoQ
The company's revenue rose by 32% QoQ

Efficiency

How efficient is Tonix Pharmaceuticals Holding business performance
The company's return on equity fell by 39% YoY but it rose by 5% QoQ
TNXP's ROS is up by 36% from the previous quarter
TNXP's return on invested capital is up by 29% year-on-year and by 18% since the previous quarter
TNXP's ROA is down by 25% YoY but it is up by 9% QoQ

Dividends

What is TNXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TNXP.

Financial health

How did Tonix Pharmaceuticals Holding financials performed over time
Tonix Pharmaceuticals Holding's total liabilities has soared by 99% YoY but it has decreased by 44% from the previous quarter
TNXP's quick ratio has plunged by 94% YoY and by 74% from the previous quarter
The debt is 91% smaller than the equity
The company's equity fell by 35% YoY but it rose by 2.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.